Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.

Détails

ID Serval
serval:BIB_BADF7F292D8B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Périodique
Cancer immunology, immunotherapy
Auteur(s)
Dislich B., Stein A., Seiler C.A., Kröll D., Berezowska S., Zlobec I., Galvan J., Slotta-Huspenina J., Walch A., Langer R.
ISSN
1432-0851 (Electronic)
ISSN-L
0340-7004
Statut éditorial
Publié
Date de publication
06/2017
Peer-reviewed
Oui
Volume
66
Numéro
6
Pages
777-786
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article
Publication Status: ppublish
Résumé
Expression analysis of programmed death-ligand 1 (PD-L1) may be helpful in guiding clinical decisions for immune checkpoint inhibition therapy, but testing by immunohistochemistry may be hampered by heterogeneous staining patterns within tumors and expression changes during metastatic course. PD-L1 expression (clone SP142) was investigated in esophageal adenocarcinomas using tissue microarrays (TMA) from 112 primary resected tumors, preoperative biopsies and full slide sections from a subset of these cases (n = 24), corresponding lymph node (n = 55) and distant metastases (n = 17). PD-L1 expression was scored as 0.1-1, >1, >5, >50% positive membranous staining of tumor cells and any positive staining of tumor-associated inflammatory infiltrates and/or stroma cells. There was a significant correlation with overall PD-L1 expression between the full slide sections and the TMA (p = 0.001), but not with the corresponding biopsies. PD-L1 expression in tumor cells >1% was detected in 8.0% of cases (9/112) and 51.8% of cases (58/112) in tumor-associated inflammatory infiltrates and/or stroma cells of primary tumors. Epithelial expression in metastases was found in 5.6% of cases (4/72) and immune cell expression in 18.1% of cases (13/72), but did not correlate with the expression pattern in the primary tumor. Overall PD-L1 expression in the primary tumor did not influence survival. However, PD-L1 expression was correlated with the number of CD3 <sup>+</sup> tumor-infiltrating lymphocytes in the tumor center, and a combinational score of PD-L1 status/CD3 <sup>+</sup> tumor-infiltrating lymphocytes was correlated with patients' overall survival.
Mots-clé
Adenocarcinoma/metabolism, Adenocarcinoma/secondary, Adenocarcinoma/surgery, B7-H1 Antigen/metabolism, Biomarkers, Tumor/metabolism, Esophageal Neoplasms/metabolism, Esophageal Neoplasms/pathology, Esophageal Neoplasms/surgery, Gene Expression Regulation, Neoplastic, Humans, Immunoenzyme Techniques, Lymphatic Metastasis, Lymphocytes, Tumor-Infiltrating/immunology, Lymphocytes, Tumor-Infiltrating/metabolism, Lymphocytes, Tumor-Infiltrating/pathology, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Survival Rate, Tumor Microenvironment, Esophageal adenocarcinoma, Immunohistochemistry, Metastases, PD-L1
Pubmed
Web of science
Création de la notice
29/06/2020 10:30
Dernière modification de la notice
30/06/2020 5:26
Données d'usage